

~~CONFIDENTIAL~~

AUG 23 2004

[illegible][illegible]

**Examiner
Signature**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 23, 2004 (Use as many sheets as necessary)		Complete if Known	
Application Number		10/076,604	
Filing Date		02/19/2002	
First Named Inventor		R. Tyler White	
Group Art Unit		1652	
Examiner Name		E. Slobodyansky	
Attorney Docket Number		056324-0129	
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ES	A16	DENNIS, M. <i>et al.</i> , "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa", <i>J. of Biol. Chem.</i> , Vol. 269, No. 35, Sept. 2, pp. 22129-136, 1994.	
ES	A17	COLMAN, R., "Factor XII Activation and Inhibition In Inflammation", <i>Proteases, Protease Inhibitors and Protease-Derived Peptides</i> , pp. 125-43, 1993.	
ES	A18	SCOTT, C. <i>et al.</i> , "Kinetics of Inhibition of Human Plasma Kallikrein by a Site-Specific Modified Inhibitor Arg ¹⁵ -Aprotin: Evaluation Using a Microplate System & Comparison with Other Proteases", <i>Blood</i> , Vol. 69, No. 5 (May), 1987: pp. 1431-36.	
ES	A19	PATSON, P. <i>et al.</i> , "Reactivity of α_1 -Antitrypsin Mutants against Proteolytic Enzymes of the Kallikrein-Kinin, Complement, and Fibrinolytic Systems", <i>J. of Biol. Chem.</i> , Vol. 265, No. 18, pp. 10786-91, June 25, 1990.	
ES	A20	WEN, L. <i>et al.</i> , "Chemical Synthesis, Molecular Cloning, Overexpression, and Site-Directed Mutagenesis of the Gene Coding for Pumpkin (<i>Curcubita maxima</i>) Trypsin Inhibitor CMTI-V", <i>Protein Expression and Purification</i> 4, pp. 215-22 (1993).	
ES	A21	PEDERSEN, L. <i>et al.</i> , "The Corn Inhibitor of Blood Coagulation Factor XIIa, Crystallization and Preliminary Crystallographic Analysis", <i>J. Mol. Biol.</i> (1994) 236, pp. 385-87.	
ES	A22	PONTE, P. <i>et al.</i> , "A New A4 Amyloid mRNA contains a domain homologous to serine proteinase inhibitors", <i>Nature</i> , Vol. 331, pp. 525-527, February 11, 1988.	
ES	A23	TANZI, R. <i>et al.</i> , "Protease Inhibitor Domain Encoded by an Amyloid Protein Precursor mRNA associated with Alzheimer's Disease", <i>Nature</i> , Vol. 331, pp. 528-530, Feb. 11, 1988.	
ES	A24	JOHNSTONE, E. <i>et al.</i> , "Alzheimer's Disease Amyloid Peptide is Encoded by Two Exons and Shows Similarity to Soybean Trypsin Inhibitor", <i>Biochem. & Biophys. Res. Comm.</i> , Vol. 163, No. 3, pp. 1248-1255, Sept. 29, 1989.	
ES	A25	WENZEL, H. <i>et al.</i> , "Semisynthetic Conversion of the Bovine Trypsin Inhibitor (Kunitz) into an Efficient Leukocyte-Elastase Inhibitor by Specific Valine for Lysine Substitution in the Reactive Site", <i>Chem. of Peptides and Proteins</i> , Vol. 3, pp. 105-117, (1986).	
ES	A26	NORRIS, K. <i>et al.</i> , "Aprotinin and Aprotinin Analogues Expressed in Yeast", Walter de Gruyter & Co., pp. 37-42, May 1990.	
ES	A27	PERONA, J.J. <i>et al.</i> , "Crystal Structures of Rat Anionic Trypsin Complexed with Protein Inhibitors APPI and BPTI", <i>J. Mol. Biol.</i> (1993) 230:919-933.	
ES	A28	SINHA S. <i>et al.</i> , "Conversion of the Alzheimer's β -Amyloid Precursor Protein (APP) Kunitz domain into a Potent Human Neutrophil Elastase Inhibitor", <i>J. of Biol. Chem.</i> , Vol. 266, No. 31, (1991), pp. 21011-13.	

Examiner Signature	E. Slobodyansky	Date Considered	11/8/04
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 23, 2004 (use as many sheets as necessary)		Application Number	10/076,604
		Filing Date	02/19/2002
		First Named Inventor	R. Tyler White
		Group Art Unit	1652
		Examiner Name	E. Slobodyansky
		Attorney Docket Number	056324-0129
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ES	A29	OLTSELDORF, T. <i>et al.</i> , "The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II", <i>Nature</i> , Vol. 341, pp. 144-147, Sept. 14, 1989.	
ES	A30	HYNES, T.R. <i>et al.</i> , "X-ray Crystal Structure of the Protease Inhibitor Domain of Alzheimer's Amyloid β -Protein Precursor", <i>Biochemistry</i> , Vol. 29, No. 43, (1990), pp. 10018-22.	
see A16	A31	DENNIS, M.S. <i>et al.</i> , "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa", <i>J. Biological Chemistry</i> , Vol. 269, No. 35, (1994), pp. 22129-36.	
ES	A32	DENNIS, M.S. <i>et al.</i> , "Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa", <i>J. Biological Chemistry</i> , Vol. 269, No. 35, (1994), pp. 22137-44.	
ED	A33	KIDO, H. <i>et al.</i> , "Protease-Specificity of Kunitz Inhibitor Domain of Alzheimer's Disease Amyloid Protein Precursor", <i>Biochemical and Biophysical Research Communications</i> , Vol. 167, No. 2, (1990), pp. 716-721.	
ES	A34	DENNIS, M.S., "Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display", <i>Journal of Biological Chemistry</i> , Vol. 270, No. 43, (1995), pp. 25411-17.	

Examiner Signature	<i>E. Slobodyansky</i>	Date Considered	11/8/04
--------------------	------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.